Advertisement

Topics

Latest "Seattle Genetics Inc." News Stories - Page: 20

04:01 EDT 22nd March 2019 | BioPortfolio

Here are the most relevant search results for "Seattle Genetics Inc." found in our extensive news archives from over 250 global news sources.

More Information about Seattle Genetics Inc. on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Seattle Genetics Inc. for you to read. Along with our medical data and news we also list Seattle Genetics Inc. Clinical Trials, which are updated daily. BioPortfolio also has a large database of Seattle Genetics Inc. Companies for you to search.

Showing "Seattle Genetics" News Articles 476–500 of 2,000+

Thursday 31st January 2019

Emblation Announces Launch of Swift in the USA

Emblation (UK), a global leader in microwave ablation technology, announce official launch of Swift Microwave therapy device into North America. EDINBURGH, United Kingdom (PRWEB) January 31, 2019 Emblation is delighted to announce that Swift®, the breakthrough microwave treatment system, is now available in the United States. The Swift® system is a surface-based device intended for the ...


Co-Diagnostics Announces $5.5 Million Registered Direct Offering

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has entered into definitive agreements with institutional investors for the purchase of 3,925,716 shares of its common stock, at a purchase price per share of $1.40, in a regis...

Genomic Prediction Raises $4.5M in Sale of Preferred Stock to Support Innovation and Growth

Genomic Prediction, developer of the world’s first and only polygenic disease screening tests for improving IVF health outcomes, announced today that it has raised $4.5 million through the sale of preferred stock. Nimble Ventures led the oversubscribed round, joined by new investors including PeopleFund, and bolstered by earlier inves...


Hitachi Chemical Co. Ltd. to Acquire apceth Biopharma GmbH, Expanding Global Footprint of its Cell and Gene Therapy Contract Development and Manufacturing Services

Hitachi Chemical Advanced Therapeutics Solutions, LLC announces an agreement by which apceth Biopharma GmbH (“apceth Biopharma”), a contract manufacturer of cell and gene therapy products, will join Hitachi Chemical’s PCT global services platform. apceth Biopharma manufactures cell and gene therapy products for American and European clients ...

As STD Rates Soar, AHF Rolls Out Condom Billboard Ad Campaigns Across U.S.

As STD rates continue to skyrocket—particularly among youth—AHF goes ‘back to basics’ on prevention with the launch of billboard and transit ad campaigns promoting condom use. Ads for LOVE and ICON brand condoms are up now in Atlanta, Chicago, Los Angeles, Miami, New York and other markets.Straightforward public health messages encouraging condom u...

Inotrem Announces an Extension of Its License Agreement for the Biomarker Soluble TREM-1 to Cardiovascular Diseases

Inotrem S.A., a biotechnology company focused on the modulation of the TREM-1 pathway for the management of acute and chronic inflammatory syndromes, announced today the signature of an exclusive license agreement with four major research organizations, under which it receives the exclusive worldwide rights for the biomarker soluble TREM-1 (sTREM-1) in car...

Repare Therapeutics Announces a Strategic Partnership Agreement With ONO Pharmaceutical Co., Ltd. for Repare’s Polθ Inhibitor Program in Japan and Selected Territories in Asia

Repare Therapeutics, Inc., a privately held precision oncology company pioneering synthetic lethality to develop novel therapeutics that target specific vulnerabilities of tumors in clearly defined patient populations, announced today that it has entered into an exclusive strategic research, development and commercialization partnership with ONO Pharmaceut...

Wednesday 30th January 2019

Excellere Partners Announces Investment in Concord Technologies, a Leading Provider of Healthcare Interoperability and Automation Solutions

Excellere Partners, a Denver-based private equity firm focused on partnering with entrepreneurs and management teams, announced today that it has made a strategic investment in Concord Technologies (“Concord”), a leading provider of secure, cloud-based interoperability and automation technology for healthcare and other document-intensive industries. Ba...

Ambry Genetics and Undiagnosed Diseases Network Team Up to Offer Hope for Patients with Undiagnosed Diseases

Collaboration holds promise to patients in search for answers and an end to their diagnostic odyssey ALISO VIEJO, Calif. (PRWEB) January 30, 2019 Ambry Genetics, a Konica Minolta Company (Ambry), and leading provider of clinical genetic testing, today announced its collaboration with the Undiagnosed Diseases Network (UDN), a NIH-funded research study dedicated to solving the most challenging medi...

Good Enough to Eat?: Next Generation GM Crops

So long as you have food in your mouth, you have solved all questions for the time being. So begins Good Enough to Eat?: Next Generation GM Crops, which challenges Kafka's culinary sentiments and proceeds to unravel our complex and deeply personal relationship with food.The book is authored by Ian Godwin, Professor in Plant Molecular Genetics and D...

Physicians’ Education Resource® Announces Keynote Speakers for the 36th Annual Miami Breast Cancer Conference®

Dr. Gregory Stock and breast cancer survivor Stephanie Seban will give keynote speeches at the conference Physicians’ Education Resource® (PER®), a leading resource for continuing medical education (CME), announces Dr. Gregory Stock and Stephanie Seban as the keynote speakers for the 36th annual Miami Breast Cancer Conference®. This year’...

CENTOGENE Develops New Validation Framework to Optimize Specificity and Sensitivity in Whole Exome Sequencing-Based Diagnostics

CENTOGENE, a rare disease company committed to improving the lives of rare disease patients by providing solutions that accelerate the development of drugs, has published the development of a rationale framework to optimize sensitivity and specificity in whole exome sequencing (WES)-based diagnostics of a clinically heterogeneous patient population ...

Prenetics Group Acquires ‘Psychologist in a Pocket’ Kelaa App

Prenetics, a Southeast Asia-based global genetics, and digital health company announced it has acquired Kelaa App, the core product of Soma Analytics and associated assets. Founded in Germany in 2013, the Kelaa’ smartphone app available on Apple and Android devices provides tailored recommendations on how to deal with day-to-day stresses through bite-sized personalized daily sessions for empl...

Sigilon Therapeutics Expands Intellectual Property Portfolio with New Patent Issued

Portfolio Covers 16 Patent Families Across Major Markets Sigilon Therapeutics, a biopharmaceutical company that discovers and develops Shielded Living TherapeuticsTM, today announced the expansion of its patent portfolio with a newly granted U.S. patent (Patent No. US 10,172,791 B2) that further builds on the company’s strong intellectual prop...

Castle Biosciences Announces Publication of Prospective Multicenter Study Demonstrating that its DecisionDx-Melanoma Test can Inform Sentinel Lymph Node Biopsy Decisions

Validation data from 1,421 patients published in Future Oncology Castle Biosciences, Inc., a skin cancer diagnostics company providing personalized genomic information to improve cancer management decisions, today announced publication of data supporting clinical use of the DecisionDx®-Melanoma test to inform decisions for use of sentinel lymph node b...

Co-Diagnostics, Inc. Announces Elimination of Debt, Additional Capital Infusion

Transaction included $3M of preferred shares, and the elimination of $2M of debt Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today the sale of $3 million of preferred shares, convertible to common stock at a fixed price of $1.20 ...

Global Genotyping Market Research Report 20122024 [Report Updated: 01011970] Prices from USD $1800

The global Genotyping market will reach Volume Million USD in 2017 with CAGR xx% 20192023. The objective of report is to define, segment, and project the market on the basis of product type, application, and region, and to describe the content about the factors influencing market dynamics, policy, economic, technology and market entry etc.Based on products type, the report describes major products...

Knopp Biosciences to Present at 2019 BIO CEO & Investor Conference

Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need, today announced that the management will present and conduct face-to-face meetings at the 2019 BIO CEO & Investor Conference, to be held in New York, NY on February 1...

Dewpoint Therapeutics Launches with $60 Million Series A to Advance Proprietary Platform for Drugging Condensates

Dewpoint Therapeutics, a company translating the emerging area of biomolecular condensates into drug discovery, launched today with a $60 million Series A. Founding investor Polaris Partners led the equity round and was joined by Samsara BioCapital, 6 Dimensions Capital, EcoR1 Capital, Alexandria Venture Investments, and Leaps by Bayer. Dewpoint i...

Wound Care: New Clinical Data Show Nexodyn® AOS to Reduce Reinfections and Healing Time in Diabetic Foot Ulcers

Results of a clinical study recently published in the scientific journal “The International journal of Lower Extremity Wound” show Nexodyn® AcidOxidizing Solution (AOS), the Tehclo based cleanser for acute and chronic wound care developed by the Swiss pharma company APR Applied Pharma Research s.a. (“APR”), to promote the restart of wound healing ...

Europe NonInvasive Prenatal Testing Market Research Report 2018 [Report Updated: 08102018] Prices from USD $1290

Europe NonInvasive Prenatal Testing market is set to touch US$ 500 Million by 2025.The market is driven by number of factors such as high incidence rate of babies born with down syndrome, no risk of miscarriage with NIPT test, shifting trend towards child bearing at advanced maternal age 35 years or older, rising focus on reimbursement for NIPT and increasing preference for noninvasive techniques ...

University of Exeter: Common Gene Disorder Causes Serious “Stealth” Disease, but Could Be Easily Treated

The western world’s most common genetic disorder, hemochromatosis, causes far higher levels of serious disease and disability than previously thought, despite being easy to detect and treat. Two major studies have revealed that hemochromatosis, previously thought to be a low-level health risk, quadruples risk of liver disease and doubles the ris...

Tuesday 29th January 2019

Genes behind lager yeast's cold- and sugar-loving success revealed

(University of Wisconsin-Madison) In a pair of new papers, University of Wisconsin-Madison Professor of Genetics Chris Todd Hittinger, his graduate student EmilyClare Baker and others show how modern lager yeast adopted the cold-loving and sugar-hungry traits essential to their success.

NewLink Genetics to Participate in the Immuno-Oncology 360° Conference

AMES, Iowa, Jan. 30, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that the Company’s Chairman, CEO and Chief Scientific Officer, Charles J. Link, Jr, MD, will participate in the Immuno-Oncology 360° Conference (IO360

Genetics Home Reference: Smith-Kingsmore syndrome

Source: National Library of Medicine - Related MedlinePlus Pages: Learning Disabilities


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks